What Are Peptides? Benefits, Risks & Medical Guidance
If you have scrolled social media, listened to a wellness podcast, or overheard a conversation at the gym lately, chances are you have heard the word peptides. They have become a major topic in aesthetics, recovery, metabolism, and longevity medicine.
The interest is understandable. Peptides are a genuinely exciting area of medicine, but the category is often oversimplified. Some peptide medications have established clinical uses, while many products promoted for wellness or recovery remain investigational, compounded, or used off-label. “Peptide” does not automatically mean proven, approved, appropriate, or safe.
What Are Peptides, Exactly?
Peptides are short chains of amino acids, the same building blocks that make up proteins. Your body naturally produces many peptides, and some help cells communicate by binding to receptors and influencing processes such as hormone signaling, immune activity, tissue repair, and metabolism.
Researchers can also create peptide-based medicines or laboratory-made versions of naturally occurring signals. That broad category includes established prescription drugs, compounds used off-label, compounded preparations, topical skincare ingredients, and experimental substances. Those categories are not interchangeable.
Why Are Peptides Getting So Much Attention?
Peptides now appear in conversations about skin quality, recovery, sleep, body composition, metabolic health, and healthy aging. Targeted biological signaling is scientifically compelling, and some peptide drugs have important clinical uses. But online discussions often group very different substances together and move faster than the evidence.
The safest approach is to evaluate each peptide individually: what it is intended to do, what evidence exists in humans, whether the proposed use is FDA-approved, how the product is sourced, and what monitoring may be appropriate.
A Closer Look at Commonly Discussed Peptides
GHK-Cu (Copper Peptide)
GHK-Cu is commonly discussed in relation to skin remodeling, wound healing, and collagen-related pathways. Many patients recognize copper peptides from topical skincare, but topical and injectable use are different questions. FDA’s May 2026 Category 1 status applies to non-injectable routes; injectable GHK-Cu remains associated with FDA-identified safety concerns and limited human data.
Sermorelin
Sermorelin stimulates the pituitary growth-hormone pathway and is often discussed in connection with sleep, recovery, and body composition. The former Geref approvals were withdrawn after the manufacturer discontinued the product, so current wellness use should not be described as an active FDA-approved indication.
Tesamorelin
Tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That is a narrow indication. Its prescribing information specifically states that it is not indicated for weight-loss management, so its approval should not be generalized to routine weight loss or body sculpting.
MOTS-C
MOTS-C is a mitochondrial-derived peptide being studied in relation to metabolism, insulin sensitivity, energy regulation, and age-related changes. Laboratory, animal, and early human observational research has generated interest, but the evidence does not yet establish routine therapeutic benefit or long-term safety for general wellness use.
BPC-157
BPC-157 is widely promoted online for injury recovery, inflammation, gut health, and tissue repair. Most supportive evidence remains preclinical. Human dosing, effectiveness, product quality, and long-term safety are not sufficiently established, and there is no FDA-approved BPC-157 drug.
What Changed in the FDA Discussion in 2026?
Regulatory access and FDA approval are not the same thing. As of July 29, 2026:
- FDA’s Category 1 document lists GHK-Cu only for non-injectable routes. Category 1 means a nominated bulk substance is under evaluation and may fall within an interim enforcement policy when specified conditions are met. It is not FDA approval.
- On July 23, 2026, the Pharmacy Compounding Advisory Committee considered BPC-157-related substances and MOTS-C-related substances for possible inclusion on the 503A Bulks List. Advisory committee recommendations are non-binding, and the meeting itself did not create FDA approval or establish a final list decision.
- Tesamorelin remains the only peptide discussed here with a current, specific FDA-approved therapeutic indication. That indication should not be generalized to routine weight loss.
Are Peptide Therapies Safe?
There is no single safety answer for all peptides. Risk depends on the compound, route of administration, dose, product quality, medical history, medications, treatment goal, and follow-up. A compounded product is not the same as an FDA-approved drug, and “naturally occurring” does not automatically mean low-risk.
Potential concerns may include:
- Contamination, sterility failures, or incorrect concentration
- Injection-site reactions and improper handling
- Immune reactions or peptide-related impurities
- Effects on glucose regulation, fluid balance, hormones, or growth-factor pathways
- Interactions with existing conditions or medications
- Unknown long-term effects when human evidence is limited
Why Physician-Led Care Matters
A responsible evaluation starts with the patient, not the product. Depending on the therapy being considered, physician-led care may include:
- A review of medical history, medications, and prior treatments
- A clear discussion of the treatment goal and realistic expectations
- Screening for contraindications and meaningful risk factors
- Baseline and follow-up laboratory testing when clinically appropriate
- Transparent discussion of FDA status, evidence quality, uncertainties, and alternatives
- A documented sourcing, storage, dosing, and follow-up plan
For injectable products, sterile technique and product provenance are central safety issues. Medical oversight should continue beyond obtaining a prescription.
Questions to Ask Before Considering a Peptide
- What is the exact peptide, and what goal is it intended to address?
- Is this use FDA-approved, off-label, compounded, or investigational?
- What human evidence supports this use, and what remains unknown?
- Where is the product sourced, and how are purity and sterility addressed?
- What side effects, contraindications, and interactions matter for me?
- What monitoring and follow-up will be provided?
- What evidence-based alternatives should I consider first?
The Bottom Line
Peptides are an important and fast-moving area of medicine, but they are not one uniform treatment category. Good decisions separate promise from proof, distinguish compounding status from FDA approval, and place patient selection, product quality, and monitoring ahead of hype.
At Arvé Aesthetics, we are carefully evaluating the evidence, sourcing requirements, and safety protocols around peptide therapy before adding any new service. If you are curious about peptides, bring your questions to an appointment. Our team can help you understand what is established, what remains uncertain, and what options may be appropriate for your goals.
Drs. Joseph & Francesco Laterza, Arvé Aesthetics
Frequently Asked Questions
Are all peptides FDA-approved?
No. Some peptide medications have specific FDA-approved indications, while many compounds promoted for recovery, aesthetics, or longevity do not.
Does Category 1 mean a peptide is FDA-approved?
No. Category 1 generally means a nominated bulk substance is under evaluation and may fall within an interim enforcement policy when specified conditions are met.
Can peptides help with weight loss?
Approval and evidence vary by drug. Tesamorelin has a narrow HIV-related indication and is not indicated for general weight-loss management.
Is BPC-157 proven to heal injuries?
Robust human trials, standardized dosing, and long-term safety data remain lacking despite substantial online interest.
Can I buy peptides online and use them myself?
Self-directed use creates avoidable risks involving identity, purity, sterility, dosing, interactions, and follow-up.
Medical information notice: This article is for general education and does not replace individualized medical advice, diagnosis, or treatment. Regulatory status and evidence can change.
Sources:
- FDA, 503A bulk drug substances: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- FDA, Category document updated May 14, 2026: https://www.fda.gov/media/94155/download
- FDA, July 23 and 24, 2026 advisory committee meeting: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- FDA, EGRIFTA WR prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
- FDA, safety risks associated with certain bulk substances: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
